Director at United Therapeutics (UTHR) exercises options, sells shares

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp director Tommy G Thompson reported multiple transactions on March 4, 2026. He exercised a stock option for 2,000 options, labeled as an exercise or conversion of a derivative security, resulting in 2,000 options held afterward.

On the same date, he acquired 2,000 shares of common stock through this option exercise at a price of $101.8000 per share, bringing his direct common stock holdings to 10,480 shares. He then executed an open-market sale of 2,000 common shares at a weighted average price of $489.4197 per share, leaving 8,480 directly held shares.

A footnote states that his direct holdings include 880 additional common shares to be issued on or about July 8, 2026 from previously vested RSUs for which receipt was deferred. Indirectly, 8,200 common shares are held by a trust and 5,800 common shares are held through a Family LLC associated with him.

Insider Trade Summary

Net Seller: 2,000 shares ($978,839)

Net Sell 5 txns

Insider Thompson Tommy G

Role Director

Sold 2,000 shs ($979K)

Type	Security	Shares	Price	Value
Exercise	Stock Option	2,000	$0.00	--
Exercise	Common Stock	2,000	$101.80	$204K
Sale	Common Stock	2,000	$489.4197	$979K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option — 2,000 shares (Direct); Common Stock — 10,480 shares (Direct); Common Stock — 8,200 shares (Indirect, by Trust)

Footnotes (1)

1. Includes 880 shares of common stock to be issued on or about July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares. This transaction was executed in multiple trades at prices ranging from $488.95 to $489.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Tommy G

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M		2,000	A	$101.8	10,480(1)	D
Common Stock	03/04/2026		S		2,000	D	$489.4197(2)	8,480(1)	D
Common Stock								8,200	I	by Trust
Common Stock								5,800	I	Family LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$101.8	03/04/2026		M			2,000	06/21/2017	06/21/2026	Common Stock	2,000	$0.00	2,000	D

Explanation of Responses:

1. Includes 880 shares of common stock to be issued on or about July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares.

2. This transaction was executed in multiple trades at prices ranging from $488.95 to $489.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did UTHR director Tommy G Thompson report?

Tommy G Thompson reported exercising 2,000 stock options and acquiring 2,000 United Therapeutics common shares, then selling 2,000 common shares in an open-market transaction, all dated March 4, 2026, according to the Form 4 filing details.

How many United Therapeutics (UTHR) shares did Tommy G Thompson sell?

He sold 2,000 shares of United Therapeutics common stock. The transaction was reported as an open-market sale, with a weighted average sale price of $489.4197 per share, executed in multiple trades within a disclosed price range.

At what prices did Tommy G Thompson trade UTHR shares on March 4, 2026?

He acquired 2,000 United Therapeutics common shares via an option exercise at $101.8000 per share, then sold 2,000 shares at a weighted average price of $489.4197 per share, with individual trades between $488.95 and $489.65.

What is Tommy G Thompson’s direct ownership in United Therapeutics after these transactions?

After these transactions, he directly holds 8,480 United Therapeutics common shares. A footnote also indicates 880 additional common shares are scheduled to be issued on or about July 8, 2026 from previously vested, deferred RSUs.

What indirect United Therapeutics (UTHR) holdings are associated with Tommy G Thompson?

Indirectly, 8,200 United Therapeutics common shares are held by a trust and 5,800 common shares are held through a Family LLC. These positions are reported as indirect ownership interests in the Form 4, separate from his directly held shares.

What does the Form 4 footnote say about the UTHR share sale prices?

The footnote explains the 2,000-share sale was executed in multiple trades between $488.95 and $489.65. The reported $489.4197 figure is a weighted average price, and full trade details are available upon request from the reporting person.